Compare Stocks

Date Range: 

 Paramount Gold NevadaBunker Hill MiningWealth MineralsPure Energy MineralsOpiant Pharmaceuticals
SymbolNYSEAMERICAN:PZGOTCMKTS:BHLLOTCMKTS:WMLLFOTCMKTS:PEMIFNASDAQ:OPNT
Price Information
Current Price$1.04$0.24$0.28$1.11$12.27
52 Week RangeBuyN/AN/AN/AN/A
MarketRank™
Overall Score1.70.50.50.50.5
Analysis Score3.50.00.00.00.0
Community Score2.52.52.52.52.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.00.0
Earnings & Valuation Score0.60.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyN/AN/AN/AN/A
Consensus Price Target$1.70N/AN/AN/AN/A
% Upside from Price Target63.46% upsideN/AN/AN/AN/A
Trade Information
Market Cap$37.68 million$35.78 million$48.17 million$35.84 million$53.14 million
Beta1.9810.361.482.110.85
Average Volume343,76632,957248,001101,31236,753
Sales & Book Value
Annual Revenue$730,000.00N/AN/AN/A$40.52 million
Price / Sales51.61N/AN/AN/A1.31
CashflowN/AN/AN/AN/A$0.41 per share
Price / CashN/AN/AN/AN/A29.89
Book Value$1.67 per share($0.42) per share$0.20 per share$0.80 per share$8.41 per share
Price / Book0.62N/AN/AN/A1.46
Profitability
Net Income$-6,430,000.00$-31,320,000.00$-13,180,000.00$-380,000.00$11.59 million
EPSN/AN/AN/AN/A$0.20
Trailing P/E Ratio0.00N/AN/A0.00N/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-0.39%
Return on Equity (ROE)-14.78%N/A-18.89%-1.57%-0.31%
Return on Assets (ROA)-12.97%-280.54%-5.10%-1.56%-0.27%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.11%N/AN/AN/AN/A
Current Ratio8.70%0.54%0.06%0.94%6.06%
Quick Ratio8.70%0.54%0.06%0.94%6.06%
Ownership Information
Institutional Ownership Percentage6.65%N/A0.01%N/A20.83%
Insider Ownership Percentage2.95%N/AN/AN/A28.02%
Miscellaneous
Employees72N/AN/A30
Shares Outstanding36.23 million143.12 million173.89 million32.29 million4.33 million
Next Earnings Date5/6/2021 (Estimated)5/21/2021 (Estimated)7/29/2021 (Estimated)5/27/2021 (Estimated)5/11/2021 (Confirmed)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Zacks: Brokerages Expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Will Announce Earnings of -$0.71 Per ShareZacks: Brokerages Expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Will Announce Earnings of -$0.71 Per Share
americanbankingnews.com - May 5 at 5:18 PM
Opiant Pharmaceuticals (OPNT) Scheduled to Post Quarterly Earnings on TuesdayOpiant Pharmaceuticals (OPNT) Scheduled to Post Quarterly Earnings on Tuesday
americanbankingnews.com - May 4 at 12:20 PM
Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Passes Above 200-Day Moving Average of $9.97Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Passes Above 200-Day Moving Average of $9.97
americanbankingnews.com - May 4 at 1:28 AM
Opiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021Opiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
finance.yahoo.com - May 3 at 6:37 PM
Is Opiant Pharmaceuticals (NASDAQ:OPNT) Using Debt Sensibly?Is Opiant Pharmaceuticals (NASDAQ:OPNT) Using Debt Sensibly?
nasdaq.com - April 29 at 7:37 PM
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expected to Announce Quarterly Sales of $5.48 MillionOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expected to Announce Quarterly Sales of $5.48 Million
americanbankingnews.com - April 20 at 3:06 AM
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expected to Announce Earnings of -$0.68 Per ShareOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Expected to Announce Earnings of -$0.68 Per Share
americanbankingnews.com - April 18 at 4:44 PM
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Sees Significant Increase in Short InterestOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Sees Significant Increase in Short Interest
americanbankingnews.com - April 17 at 1:01 PM
Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Crosses Above 200-Day Moving Average of $9.58Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Crosses Above 200-Day Moving Average of $9.58
americanbankingnews.com - April 13 at 1:00 AM
Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal ...Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal ...
apnews.com - April 6 at 9:10 AM
Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal NaloxoneOpiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
finance.yahoo.com - April 5 at 6:35 PM
The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands ContractThe Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract
markets.businessinsider.com - April 1 at 9:09 AM
Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational ...Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational ...
apnews.com - March 31 at 6:08 PM
Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid OverdoseOpiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
finance.yahoo.com - March 31 at 6:08 PM
Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical ...Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical ...
apnews.com - March 23 at 4:32 AM
Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
feeds.benzinga.com - March 22 at 4:28 PM
OPNT: NDA Filing on Track for 4Q21…OPNT: NDA Filing on Track for 4Q21…
finance.yahoo.com - March 9 at 1:13 PM
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Just Released Its Full-Year Earnings: Heres What Analysts ThinkOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Just Released Its Full-Year Earnings: Here's What Analysts Think
finance.yahoo.com - March 6 at 9:23 AM
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides ...Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides ...
apnews.com - March 6 at 12:18 AM
The Daily Biotech Pulse: Fulgents Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 StudyThe Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
markets.businessinsider.com - March 5 at 9:15 AM
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 4 at 8:21 PM
Recap: Opiant Pharmaceuticals Q4 EarningsRecap: Opiant Pharmaceuticals Q4 Earnings
finance.yahoo.com - March 4 at 8:21 PM
Opiant Pharmaceuticals Inc hosts conference call for investorsOpiant Pharmaceuticals Inc hosts conference call for investors
markets.businessinsider.com - February 26 at 12:54 PM
Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021
finance.yahoo.com - February 22 at 7:43 PM
The Opiant Pharmaceuticals (NASDAQ:OPNT) Share Price Is Up 45% And Shareholders Are Holding OnThe Opiant Pharmaceuticals (NASDAQ:OPNT) Share Price Is Up 45% And Shareholders Are Holding On
finance.yahoo.com - February 22 at 9:41 AM
DateCompanyBrokerageAction
3/29/2021Paramount Gold NevadaRoth CapitalReiterated Rating
7/15/2020Paramount Gold NevadaCanaccord GenuityReiterated Rating
7/2/2020Paramount Gold NevadaAlliance Global PartnersBoost Price Target
5/1/2020Opiant PharmaceuticalsNorthland SecuritiesReiterated Rating
10/4/2018Opiant PharmaceuticalsCantor FitzgeraldSet Price Target
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.